Company profile: Plex Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of therapeutics for neurodegenerative disorders and CNS tumors, including modulators of heat shock proteins and FK506 Binding Protein for ALS and Parkinson's disease, dual HSP90/TRAP1 inhibitors for glioblastoma, and non-surgical cataract treatments; enabled by a core platform that combines functional fragment screening with X-ray crystallography and a proprietary fragment library to identify and evolve drug leads.
Products and services
- Neurodegenerative Disorder Treatments: Engineers custom-engineered modulators of heat shock proteins and FK506 Binding Protein to treat ALS and Parkinson’s disease, translating seminal academic discoveries into therapies
- Core Technology Platform: Architects a structure-guided system that combines functional fragment screening with X-ray crystallography to design New Chemical Entities for neurodegenerative disorders
- CNS Refractory Tumors Treatment: Develops dual-target HSP90/TRAP1 inhibitors to treat central nervous system tumors, including glioblastoma, progressing therapies for refractory CNS malignancies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Plex Pharmaceuticals
Vanda Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies focused on central nervous system disorders, developing and commercializing innovative products through clinical and commercial stage programs, including HETLIOZAccess: an expanded access program for Non-24-Hour Sleep-Wake Disorder (Non-24).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vanda Pharmaceuticals company profile →
Supernus Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products for central nervous system diseases, developing and commercializing therapies including Qelbree for ADHD; Trokendi XR for epilepsy and migraine prevention; and Oxtellar XR for epilepsy, with pipeline candidates SPN-830 for hypomobility in Parkinson’s disease, SPN-820/821 for treatment-resistant depression, and SPN-817 for severe epilepsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Supernus Pharmaceuticals company profile →
Rapport Therapeutics
HQ: United States
Website
- Description: Provider of precision medicines for neurological disorders, leveraging a RAP Technology Platform to discover and develop small-molecule therapies targeting specific neuronal receptor complexes. Programs include TARPγ8 AMPAR small molecules in clinical development for epilepsy with potential in pain and bipolar disorder, and discovery-stage nAChR modulators for chronic pain and hearing disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rapport Therapeutics company profile →
Cadent Therapeutics
HQ: United States
Website
- Description: Provider of novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease, leveraging a precision neuroscience approach combining target specificity, patient selection, and drug design and optimization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cadent Therapeutics company profile →
Inscopix
HQ: United States
Website
- Description: Provider of neural activity imaging solutions for freely behaving subjects, enabling links between circuit dynamics and behavior. Offers the nVue dual-color system with expanded storage for longitudinal studies, the LScape module for wider field of view and longer working distance in cortical imaging, and Multicolor Data Processing software for streamlined miniscope analysis with PCA/ICA or CNMFe, filtering, and longitudinal registration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inscopix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Plex Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Plex Pharmaceuticals
2.2 - Growth funds investing in similar companies to Plex Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Plex Pharmaceuticals
4.2 - Public trading comparable groups for Plex Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →